Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626097 | 0.92 | KDM4E (0.61) | KDM4EHTTPOLBHPGDGRM3 | |
| SCHEMBL13353200 | 0.87 | POLB (0.68) | KDM4EHTTPOLBHPGDGRM3 | |
| SCHEMBL12622121 | 0.87 | HTT (0.53) | KDM4EHTTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL12626113 | 0.84 | KDM4E (0.64) | KDM4EHTTPOLBHPGDUSP2 | |
| SCHEMBL20791879 | 0.84 | KDM4E (0.64) | KDM4EHTTPOLBHPGDGRM3 | |
| SCHEMBL12655508 | 0.83 | HTT (0.62) | KDM4EHTTPOLBUSP2SMN1; SMN2 | |
| SCHEMBL12655726 | 0.81 | L3MBTL1 (0.60) | KDM4EHTTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL12673396 | 0.81 | HTT (0.47) | KDM4EHTTPOLBHPGDSMN1; SMN2 | |
| SCHEMBL12621891 | 0.81 | HTT (0.47) | KDM4EHTTPOLBHPGDCYP3A4 | |
| SCHEMBL17966169 | 0.80 | POLB (0.72) | POLBHPGDGRM3USP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022098700-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | CASSAVA SCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2014011917-A2 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BURNS BARBIER LINDSAY | 2010-11-04 | — | — | US | disclosed |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BURNS BARBIER LINDSAY | 2010-11-04 | — | — | US | disclosed |
| WO-2010051476-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | KDM4E 2446/4885HTT 3666/4885POLB 2825/4885 |
| US-10363239-B2 | Method for inhibiting growth of cancer cells | FLNA, FLNB, FSCN1 | KDM4E 3556/4885HTT 2215/4885POLB 2667/4885 |
| US-20190136184-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | KDM4E 2906/4885HTT 281/4885POLB 2356/4885 |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | KDM4E 2446/4885HTT 3666/4885POLB 2825/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | KDM4E 2906/4885HTT 281/4885POLB 2356/4885 |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | FLNA, OPRL1, FLNB | KDM4E 4311/4885HTT 3245/4885POLB 3806/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | KDM4E 2906/4885HTT 281/4885POLB 2356/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | KDM4E 2906/4885HTT 281/4885POLB 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.